Ahsan et al. [83] prepared anti-toll-like receptor (TLR4) antibody-modified nanoparticles to target the TLR4, which is highly expressed on the corneal epithelial cells when infected to treat keratitis. The gene discussed is TLR4; the disease is keratitis.